Mazzariol Annarita, Bazaj Alda, Cornaglia Giuseppe
a Department of Diagnostics and Public Health , University of Verona , Verona , Italy.
J Chemother. 2017 Dec;29(sup1):2-9. doi: 10.1080/1120009X.2017.1380395.
Urinary tract infections (UTIs) are among the most frequent infectious diseases affecting humans, and represent an important public health problem with a substantial economic burden. Due to the high empiric use of antibiotics for the treatment of UTI, antibacterial resistance of Enterobacteriaceae, specifically the main uropathogens Escherichia coli and Klebsiella pneumoniae, has significantly increased worldwide. In this article the worldwide epidemiology of resistant Gram-negative bacteria causing UTIs, with a special focus on extended spectrum beta lactamase (ESBL) positive pathogens, as well as new threats such as multi-drug-resistant (MDR) clones (e.g. E. coli 131 (ST131) and K. pneumoniae ST258), are reviewed. The increased prevalence of MDR Enterobacteriaceae, limiting available treatment options for infections caused by these organisms, and the lack of new antibiotics provide good rationale for using older antibiotics, such as fosfomycin, that have been shown to retain some activity against MDR bacteria.
尿路感染(UTIs)是影响人类的最常见传染病之一,是一个重要的公共卫生问题,带来了巨大的经济负担。由于治疗UTI时抗生素的经验性使用频率很高,肠杆菌科细菌的抗菌耐药性,特别是主要的尿路病原体大肠杆菌和肺炎克雷伯菌,在全球范围内显著增加。本文综述了引起UTI的耐药革兰氏阴性菌的全球流行病学,特别关注超广谱β-内酰胺酶(ESBL)阳性病原体,以及新出现的威胁,如多重耐药(MDR)克隆(如大肠杆菌131(ST131)和肺炎克雷伯菌ST258)。MDR肠杆菌科细菌的患病率增加,限制了针对这些病原体引起的感染的可用治疗选择,而且缺乏新的抗生素,这为使用老抗生素(如磷霉素)提供了充分的理由,磷霉素已被证明对MDR细菌仍保留一定活性。